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Epithelial ovarian cancer (EOC) is a silent killer that strikes with few, if any, symptoms.  By the 
time a woman is diagnosed with EOC, it is often at an advanced stage where the outlook is grim.  
However, if caught early, the prognosis is excellent as it can be cured in up to 90% of patients.  
Therefore, developing a highly specific blood-based test is extremely appealing for pre-
symptomatic screening and early detection of EOC.  However, all blood biomarkers to date lack 
the necessary sensitivity/specificity for early detection of this disease. A fundamental challenge 
in biomarker discovery is the extremely low concentrations released from developing tumors into 
the circulation at pre-clinical stages, which can be 104-fold lower than the clinically detectable 
levels.  For this reason there is a pressing need to uncover novel biomarkers, and apply new 
strategies to propel the advancement of EOC diagnostics.  We have focused our efforts on 
extracellular vesicles (EVs), primarily exosomes derived from the endolsosomal pathway that 
play important roles in intercellular communication, immune responses and cancer pathogenesis 
via transfer of a selective repertoire of biomolecules.  A proteomic analysis was performed on 
plasma and EV depleted plasma obtained from patients diagnosed with stage III/IV serous 
ovarian cancer (n=14).  Bead-based Luminex flow cytometry assays were performed on the 
complete or EV/exosome-free plasma samples to examine circulating or EV-associated levels of 
23 growth factors, cytokines, and other cancer related molecules. In addition, similar 
experiments were completed using immune-purified CA125+ (EOC associated marker) 
subpopulation of cell culture derived exosomes.  Immunoprecipitation was also utilized to isolate 
three subtypes (CA125+, EpCAM+, and FAPa+) of extracellular vesicles, primarily exosomes, 
from plasma.  Our proteomic analysis indicated that the levels of several circulating biomarkers 
decrease upon the removal of EVs from total plasma (TRAIL, leptin, and OPN), likely indicating 
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a direct association between these analytes and EVs.  Three of the 23 analytes were specifically 
detectable in immunoisolated CA125+ cell culture derived exosomes (OPN, HE4, CYFRA-21) 
and undetectable in the unfractionated exosome population.  Of the 23 analytes investigated 21 
were detectable at varying levels in the three subtypes of EVs immuno-captured from plasma. 
When the growth factors, cytokines, and other cancer related molecules were examined in the 
subpopulations of EVs derived from cases and controls we found that using CA125 or EpCAM 
as the capture agents, and subsequently measuring CA125 and CYFRA21-1, respectively, may 
offer improved specificity and sensitivity for ovarian cancer.  This study is the first to report free 
versus microvesicle-associated proteins in EOC plasma samples, and further characterize a 
limited number of intravesicular proteins in subtypes of EOC EVs. Our work presents the 
framework for developing an ovarian cancer specific assay to capture and evaluate protein 
signatures in tumor-derived EVs, primarily exosomes, with the goal of significantly improving 
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Chapter 1. Introduction 
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1.1 Ovarian Cancer 
Ovarian cancer only accounts for 3% of cancers in women; however, it is the fifth most common 
cause of cancer death in women and the leading cause of death of all gynecological cancers (1). 
In 2016 it is estimated that over 22,000 women will receive a new diagnosis, and over 14,000 
will succumb to the disease.  The five-year survival rate for this disease ranges from 22% to 
92%, depending on the stage at diagnosis.  The average five-year survival is only 44%.  When a 
patient is diagnosed with localized disease the five-year survival is over 90% while distant and 
unstaged disease is roughly a quarter of that.  Strikingly only 15% of cases are diagnosed when 
the disease is localized and survival is promising, while an astounding 60% of cases are 
diagnosed when the disease is distant and has a dismal five-year survival rate (2).  Over the years 
the five-year survival rate for ovarian cancer has improved slightly due to improvement in 
treatment options; however, the overall rate of cure has not increased, which is impart due to the 
late stage at diagnosis (3).  When compared to other cancers, the death rate per 100,000 females 
has remained relatively unchanged for ovarian cancer (7.5 per 100,000) while most cancers have 
decreased during the past 40 years (from 1975 to 2013) (2). 
While the lifetime risk of ovarian cancer is relatively low (1 in 72) compared to other forms of 
cancers (1 in 8 for breast), there are a number of risk factors which increase a woman’s chance of 
developing ovarian cancer (3, 4).  Half of all cancers, including ovarian, show an association 
with modifiable risk factors such as: obesity, lack of physical activity and smoking (5-7).  One 
risk factor specific to ovarian cancer is hormone replacement therapy.  Women who underwent 
hormone replacement therapy were 37% more likely to develop ovarian cancer as opposed to 
women who never received hormone replacement therapy both estrogen-only and estrogen-
progesterone formulations (5).        
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There is also an increased risk of developing ovarian cancer associated with an increase in 
ovulatory cycles as described by the incessant ovulation hypothesis.  The incessant ovulation 
hypothesis correlates tumor formation as a result of an accumulation of mutations from the 
repetitive wounding and recurring cell proliferation associated with postovulatory repair of the 
ovarian surface epithelium (8).  Support for this hypothesis comes from the majority of women 
diagnosed with ovarian cancer being post-menopausal and in the sixth and seventh decade of 
life, when they have reached their maximum number of ovulatory cycles (8, 9).  Further support 
for the incessant ovulation hypothesis is shown through factors capable of suppressing or 
interrupting ovulation thus protecting against ovarian cancer (10-13).  Ovulation cycles can be 
interrupted and suppressed through the use of oral contraceptives, polyparity, breast feeding and 
tubal ligation, all of which reduce the chance of developing ovarian cancer (9, 10, 14). 
Endometriosis is another means by which a woman’s risk for ovarian cancer can be increased, 
specifically clear cell ovarian cancer.  In a genomic study conducted by Prowse et al. a total of 
63 loss of heterozygosity (LOH) events were detected in carcinomas, 22 of which were detected 
in corresponding endometriosis samples.  When comparing genomic profiles from endometriosis 
samples with that of carcinomas that later developed, in each case the same allele was lost in the 
endometriosis and carcinoma samples; however, no markers showed LOH in the endometriosis 
samples alone (15).  This data is supportive for the hypothesis that endometriosis is a precursor 
to ovarian cancer, and shows that women with endometriosis are at a higher risk of developing 
ovarian cancer. 
To date the most significant factors influencing the development of ovarian cancer come from 
family history and genetics.  The risk of developing ovarian cancer is most elevated in woman 
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with a family history of ovarian and/or breast cancer, as well as by germline mutations in BRCA1 
and BRCA2 (8).  Women in the general population have a risk of <2% of developing ovarian 
cancer; however, inheriting mutations in BRCA1 or BRCA2 increase the lifetime risk to 
approximately 40% and 20%, respectively (9, 10, 16, 17). Factors that are known to influence 
and suppress ovulatory cycles have also been shown to decrease the risk of ovarian cancer in the 
population of women with an inherited susceptibility (10).  While these epidemiological facts 
and statistics are used to describe ovarian cancer as a whole it is also vital to note the importance 
of the histological origin of the disease and the role it plays in progression and overall survival. 
Ovarian cancer can be classified based on the tissue of origin (surface epithelial, stromal 
endocrine cells, and germ cells).  Carcinomas of the epithelial origin account for >90% of 
ovarian cancer cases (18).  Transformed cells can also develop into serous, mucinous, clear cell 
and endometrioid histotypes.  Serous ovarian cancer can exist as low and high grade subtypes.  
Low grade or type I carcinomas are more often identified in the early stages and progress more 
slowly than high grade or type II carcinomas.  High grade carcinomas tend to present at the more 
advanced stages and are more aggressive (3).  For instance 86% of high grade serous ovarian 
cancer cases present at late stage as compared to only 3% of low grade serous ovarian cancer 
cases (19).  A majority of all ovarian cancer cases as well as deaths are attributed to advanced 
stage, high grade epithelial serous ovarian cancer (3, 20).  For this reason, it is desirable to find a 
means of detecting these high grade cases before they have advanced. 
Advanced cases are associated with the FIGO stage at which the carcinoma is detected as 
determined by a gynecologic oncologist.  Staging is an assessment of how far the disease has 
spread and typically performed when samples are collected for the pathologist’s analysis.   
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Staging has been standardized by the International Federation of Gynecology and Obstetrics 
(FIGO) and is typically the most important predictor of overall survival.  Ovarian cancer can 
present anywhere from stage I to stage IV with increasing severity respectively (21). 
Stage I disease can be broken up into three subcategories IA, IB, and IC.  To be classified as 
stage I the disease must be confined to the ovaries.  Detecting ovarian cancer at stage I is when 
the disease is the most curable and has the greatest overall survival rate.  The disease has 
progressed to stage II when the tumor extends into other pelvic structures and can also be 
identified based on three sub-categories: IIA, IIB, and IIC.  Progression to stage III has occurred 
when the tumor has spread beyond the pelvis into the lining of the abdomen and/or to the 
regional lymph nodes and can also be subdivided into IIIA, IIIB, and IIIC.  Greater than 50% of 
all cases are diagnosed at stage III. Descriptions of the subcategories for stage I, stage II, and 
stage III are shown in Table 1.  Stage IV disease is characterized by metastasis to distant 
locations beyond the peritoneal cavity, such as the liver and lungs (21).  Unfortunately, these late 
stages, where the disease has spread beyond the pelvis and/or metastasized, are where a majority 
of cases as diagnosed and treatment options are limited.   
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Table 1: FIGO Ovarian Cancer Staging 
Stage I Confined to Ovaries 
IA 1 Ovary 
IB 2 Ovaries 
IC 1/2 Ovaries + Capsule rupture/Tumor at surface/Malignant ascites 
Stage II 1/2 Ovaries + Pelvic Extension 
IIA Uterus/Tubes 
IIB Other pelvic organs 
IIC A/B with malignant ascites 
Stage III 1/2 Ovaries + Peritoneal Metastases /Regional lymph nodes 
IIIA Micro-scopic peritoneal metastases 
IIIB Macro-scopic (<2cm) peritoneal metastases 
IIIC Macro-scopic (>2cm) peritoneal metastases or regional lymph node metastases  
 
Symptomology, or lack thereof, also plays a significant role in the late stage at diagnosis seen 
with ovarian cancer.  The symptoms associated with ovarian cancer include bloating, pelvic or 
abdominal pain or pressure, abdominal swelling, dyspepsia, and early satiety (9, 22, 23).   These 
vague abdominal symptoms coupled with the age at onset, are often the reason ovarian cancer is 
often misdiagnosed as early menopause or gastrointestinal problems.  Only after the symptoms 
persist does a woman go on to receive additional screening such as transvaginal ultrasonography 
(TVUS) and monitoring of cancer antigen 125 (CA125).  While TVUS and CA125 are the most 
reliable screening methods to date, challenges associated with distinguishing between diseased 
and disease free women still exist. 
The only 100% specific and sensitive test for ovarian cancer is histological examination of 
biopsy samples; however, histological examination cannot be implemented as a screening 
technique and is typically only utilized after other screening methods has suggested further tests 
be completed.  When a woman has symptoms of ovarian cancer and/or a suspicious pelvic mass, 
a serum CA125 test and an abdominal and vaginal ultrasound is requested (24).  Based on the 
patient’s menopausal status, ultrasound findings, and CA125 level the risk of malignancy index 
 7 
(RMI) is calculated (24). RMI, is a simple scoring system used for evaluating the risk of ovarian 
cancer in women and is typically utilized because it gives much better results than using a single 
parameter to calculate risk (25). Even still the diagnosis of ovarian cancer is often prolonged as 
the only one and true test involves an invasive biopsy followed by histological examination.  
Coupled with the symptoms associated with ovarian cancer being vague and nonspecific a tumor 
specific biomarker for diagnostic and screening purposes is greatly sought-after. 
Ideally a tumor marker would be able to detect subclinical disease, monitor the response to 
treatment and identify early recurrence.  To date the best tumor marker for ovarian cancer is 
CA125.  CA125 is a large, 200 kd, glycoprotein expressed in coelomic epithelium during 
embryonic development (25).  In the early 1980’s Canney et al., performed some of the initial 
studies using CA125 for detection and monitoring of ovarian cancer. In initial studies a cutoff 
value of >35 U/mL was set and the radioimmunoassay provided an overall sensitivity of 83% for 
all ovarian cancer histological subtypes with a specificity of 58%.  In this initial study, CA125 
levels positively correlated with tumor burden (25).  The discovery of this antigen offered an 
alternative and less invasive means to monitoring disease progression, as opposed to the 
laparotomies previously utilized.  A quarter of a century later and CA125 is still the superior 
biomarker for ovarian cancer detection and monitoring, making it the only marker approved for 
clinical use.  While the discovery of CA125 was groundbreaking in the ovarian cancer field, 
limitations that were present at the time of initial discovery are still present today, including 
specificity, sensitivity, and ability to detect the disease in the early stages. 
In a phase I study CA125 was elevated in 82% of women with epithelial ovarian cancer and only 
1% of healthy donors.  However, CA125 is not specific to ovarian cancer and can be elevated in 
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various other forms of cancer such as lung, breast, pancreas, and colorectal (25). In addition, 
elevated levels of CA125 can be attributed to numerous benign gynecologic and non-
gynecologic diseases (24).  For these reasons CA125 is not a reliable tumor biomarker as 
elevated levels are not always a result of ovarian cancer. 
In addition to the problems associated with low specificity, the sensitivity of CA125 is lower 
than ideal.  There is a subpopulation of women diagnosed with ovarian cancer, approximately 
20%, who will not have elevated serum levels of CA125, making disease undetectable with this 
antigen (24).  In addition, the sensitivity of this marker is low for detecting early stage disease 
due to CA125 only being elevated in 25% to 50% of patients with stage I ovarian cancer (9, 24, 
26, 27).  Not all tumors cells express the antigen and the lack of sufficient antigen released by 
small tumors, contribute to CA125 levels not being elevated and detection via CA125 almost 
impossible, especially at the pre-clinical stages (25).  Thus the need still exists to develop a 
diagnostic assay or screening procedure capable of detecting ovarian cancer at the earliest 
possible time point. 
To improve upon the sensitivity of CA125 and the ability to detect early stage disease, 
transvaginal ultrasounds are being examined as a supplemental tool or alternative to CA125.  
Three large studies have been conducted examining transvaginal ultrasound as a screening 
method; however, in each of these studies TVUS did not offer the desired positive predictive 
value of 10%.  Based on the prevalence of the disease the annual cost would be too significant to 
implement TVUS as a primary screening tool (28-31).  However, TVUS may prove to be an 
excellent supplement to CA125 screening.  It has been reported that when the two methods are 
combined a specificity of 99.9% was achievable (31, 32).  Two separate screening studies were 
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conducted examining different modalities for screening and the effects on mortality due to 
ovarian cancer.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial 
screened women of the general population with CA125 and transvaginal ultrasound.  The second 
study was one of the largest to date and conducted by the UK Collaborative Trial of Ovarian 
Screening (UKCTOCS) examining three screening procedures. 
The PLCO screening trial randomly assigned over 78,000 women to two groups, annual 
screening or usual care.  The screening cohort received CA125 screening for 6 years in addition 
to screening with transvaginal ultrasound for 4 years, while the control group received neither 
screening method only usual medical care.  Women in this study were followed for 13 years to 
assess the mortality associated with ovarian cancer.  The results from this study showed that 
among the general population simultaneous screening with CA125 and transvaginal ultrasound 
did not reduce the mortality associated with ovarian cancer (33).  Even though combining TVUS 
with CA125 has shown to improve specificity at diagnosis the combination does not prove to be 
of much utility for screening purposes. 
Similar to the PLCO Screening Trial, the UKCTOCS conducted a study examining the effects of 
screening on mortality in a much larger cohort, with over 200,000 women.  These women were 
randomly allocated to three screening groups: annual multimodal screening (MMS) with CA125 
and the risk of ovarian cancer algorithm (ROCA), annual transvaginal ultrasound screening 
(USS), or no screening (34).  In the MMS group ROCA was used to monitor serum CA125 
levels over time and identify any significant rises.  Women were triaged via ROCA based on 
their risk as normal, intermediate, or elevated.  For women identified as having an elevated risk 
TVUS was used as a second-line test following the CA125 screening.  In an interim report 
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Menon and colleagues reported that the sensitivity for early stage disease increased from a 
historical baseline of 20% under standard care to almost 50% (35).  Additional analyses by the 
UKCTOCS found that for each ovarian and peritoneal cancer detected by screening, an 
additional two women in the MMS group and ten women in the USS group had false-positive 
surgery and furthermore the decrease in mortality as a result of screening was not significantly 
(33, 34).  This study conducted by UKCTOCS is the largest study to date and the results show 
that for the general population screening using MMS based on circulating CA125 and ROCA 
does not reduce ovarian cancer mortality, and there is no significant benefit associated with 
multimodal screening or transvaginal ultrasound screening (33, 34).  Since, the sensitivity with 
ROCA, for early stage disease is limited to 50%; other plasma protein biomarkers such as HE4, 
CA72.4, and MMP7 have been studied to evaluate whether they complement serum CA125 and 
thus increase sensitivity for pre-diagnostic early stage disease while maintaining specificity at 
98% (36).  These studies support the need for a novel screening method if we truly hope to 
combat the challenges associated with ovarian cancer mortality. 
The results of the UKCTOCS trial further support the U.S. Preventive Services Task Force 
(USPSTF) recommendation against screening for ovarian cancer (37).  The USPSTF found that 
as a result of the low prevalence rate of ovarian cancer the positive predictive value of screening 
is low and a majority of positive tests are actually false-positives (37).  Another major 
consideration in this recommendation comes from the balance of benefits and harms associated 
with screening.  Screening can lead to major surgical interventions in women without cancer; 
therefore, harms associated with screening outweigh the benefits.  For instance, based on false-
positive screening alone twenty-one major complications occurred per one hundred procedures 
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performed (37).  If the number of false positives could be limited, or even eliminated, screening 
could more easily be implemented in the general population. 
An alternative to screening the general population would be screening only woman with an 
elevated risk of ovarian cancer.  In a study conducted by Terada and colleagues, data from the 
Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial, previously mentioned, 
was used to analyze the effects of screening on a subcategory of women with an increased risk of 
ovarian cancer.  The study focused on menopausal women who reported a first degree relative 
with breast or ovarian cancer and examined overall mortality and disease specific mortality in the 
screening versus usual care groups. Although there was a slight shift in the stage at detection as 
well as survival, there was no significant difference in overall mortality or disease specific 
mortality between the screening group and the control group (38).  This further supports the 
limitations associated with the markers currently available for screening. 
For these reason, there has been a significant amount of research focused on trying to find 
alternatives or supplements to CA125 to create an efficient mode of screening.  Various studies 
have been conducted with the aim of finding a single marker to replace CA125, or panels that 
could be used to replace or be used in combination with CA125 (36, 39, 40).  All of these studies 
use CA125 as the standard and the performance of these candidate biomarkers are only studied 
in cases at diagnosis when the disease is already detectable with current procedures (36).  In 
addition, various studies have been conducted implementing varying techniques for screening 
purposes; however, still there exists no data supporting a beneficial, reasonable and affordable 
method for screening (40-49).  Even with all of the research aimed at finding a novel screening 
technique we are still solely reliant on a marker discovered in the early 1980’s.  
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CA125 has also been used to monitor disease recurrence as well as response to treatment.  Once 
an advanced-stage diagnosis has been confirmed a patient will undergo a cytoreductive 
debulking surgery to reduce tumor to the point where there is no grossly visible tumor (50, 51).  
Following debulking first-line chemotherapy is administered in the form of intravenous 
paclitaxel.  Paclitaxel is often times combined with carboplatin in both advanced-stage cases as 
well as those cases with early stage disease (50).  Despite the course of treatment ovarian cancer 
has the tendency to recur.  Of the women who present with advanced-stage disease two-thirds 
will recur, for which a cure remains elusive (50).  Following neoadjuvant chemotherapy, CA125 
is typically monitored as a means of evaluating response to treatment, specifically monitoring for 
recurrence (52-55).  In one study elevated levels were able to detect recurrent disease in 70% of 
patients (3).  In another study CA125 was monitored every three months for women in complete 
clinical remission following front-line therapy.  When a woman’s CA125 level exceeded twice 
the upper limit of normal she either remained blinded until symptomatic recurrence or became 
un-blinded and underwent second-line treatment.  Women who were unblended started second-
line treatment five months earlier than women who remained blinded until symptomatic 
recurrence.  However, this earlier treatment did not contribute to an overall improvement in 
survival (50, 56).  While CA125 is clinically used and approved by the FDA for monitoring 
patients following treatment the same limitations exist that exist when using CA125 as a 
screening biomarker, therefore there is a pressing need to identify new diagnostic and disease 
monitoring biomarkers. 
If we hope to decrease the mortality associated with ovarian cancer the most promising tactic 
will be to implement screening as a means of detecting early-stage disease, when patients have 
an increased survival advantage.  To date the benefits associated with screening have been less 
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than ideal.  The lack of success associated with screening thus far is likely due to a majority of 
trials utilizing CA125, even though CA125 has been shown to lack sensitivity or specificity as a 
primary test in detection.  As a result, the race to find a new diagnostic tool continues. 
1.2 Extracellular Vesicles and Exosomes  
The term “extracellular vesicle” (EV) is one that has been coined in recent years to refer to a 
range of small lipid-bounded vesicles secreted into the extracellular space.  There are three 
subcategories of EVs recognized today, 1. exosomes 2. microvesicles 3. apoptotic bodies (57-
59).  Distinguishing between the populations is often based on size, density, subcellular origin, 
function and molecular cargo (59, 60).  The secretion of extracellular vesicles is an 
evolutionarily conserved process, suggesting biological significance to the vesicles.  In recent 
years research in the field has led to the belief that cancer cells rely extensively on EVs to invade 
tissues and propagate oncogenic signal at distances (58, 59, 61).  While the term EV 
encompasses a range of vesicles a significant amount of research in the field has focused 
primarily on exosomes and their role in cancer development and communication. 
Exosomes are membrane bound microvesicles secreted by most cells in vitro and in vivo.  First 
discovered in the 1980’s exosomes were thought to be a waste removal system for the cell, 
specifically maturing reticulocytes, removing unneeded membrane proteins. Following the initial 
discovery of exosomes, four decades of intensive research has gone into understanding their 
biological significance revealing functions far beyond “waste removal systems”; however, there 
still lies an overabundance of questions regarding their biological function.  Exosomes are 
commonly described as nucleus-free, mitochondria free, membrane bound microvesicles ranging 
in size from 40-100 nm.  Vesicles are characterized as exosomes based on their structure 
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(bilipidic layer), size, density (1.13 g ml-1 to 1.19 g ml-1), and overall protein content.  Exosomes 
are representative of their cell of origin, as depicted by their protein content.  There are also a 
number of proteins which are found in a vast majority of exosome preparations and are known as 
exosomal markers.  These include members of the tetraspanin family such as CD9, CD63, and 
CD81, members of the Endosomal Sorting Complexes Required for Transport (ESCRT) such as 
ALIX and TSG101 and heat shock proteins such as Hsp70 and Hsp90 (62-66).  
The term ‘exosomes’ was initially used by Trams and colleagues in the early 1980s to describe 
exfoliation of membrane bound ecto-enzymes, with 5’nucleotidase activity (64, 67, 68).  Half a 
decade later Johnstone and colleagues observed vesicles released during the maturation of 
reticulocytes to erythrocytes, these vesicles would later come to be known as exosomes and 
refers to exosomes as we know them today.  Not only was the report of these extracellular 
vesicles a significant discovery, Johnstone was able to link the biogenesis of exosomes to the 
formation of multivesicular bodies (MVB) through tracking of the transferrin receptor.  
Johnstone was not the first to track the transferrin receptor and the formation of MVBs; however, 
she was the first to link the process to the biogenesis of exosomes (69-72).  During that time the 
transferrin receptor had been tracked during the maturation of reticulocytes and found to be 
internalized into large (1-1.5 µm in diameter) MVBs which harbored round bodies ~50 nm in 
diameter.  These 50 nm vesicles contained the transferrin receptor at the external surfaces, and 
were released into the extracellular milieu upon the fusion of MVB with the plasma membrane, a 
key component of the biogenesis process as we know it today (69-72). 
While there are still many questions regarding the biogenesis of exosomes, the process has been 
well characterized by the inward budding of the plasma membrane followed by the formation of 
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early endosomes, which mature to late endosomes ultimately forming the MVB that will later 
fuse with the plasma membrane to release microvesicles (exosomes); as shown in Figure 1.1.  
Inward budding of the plasma membrane occurs, leading to the formation of endocytic vesicles, 
through clathrin-mediated or non-clathrin-mediated endocytosis, these vesicles are then 
transported to the early endosome (63, 73).  The early endosome undergoes inward budding of 
the limiting membrane to form intraluminal vesicles (ILV).  There are various components of the 
endosomal sorting complex required for transport (ESCRT) associated with this process; 
ESCRT-0, I, II & III, TSG101, and accessory proteins as well such as VPS4.  During this time 
the early endosome undergoes acidification and changes in protein content, fully maturing into 
late a endosome (63, 73).  ESCRT complexes and accessory proteins are also involved in this 
phase of biogenesis by assisting in ubiquitin-mediated cargo trafficking, and scission of ILVs 
(62, 63, 74, 75).  The late endosome undergoes reversed budding leading to the formation of 
MVBs, which have two fates.  Once the MVB has been formed it can fuse to the lysosome 
resulting in degradation or fuse with the plasma membrane releasing microvessicle cargo, known 
as exosomes.  Members of the RAB GTPase family are responsible for this trafficking and fusion 
of the MVB to the plasma membrane (76, 77).  Many cell types release exosomes in this fashion: 
hematopoietic cells, reticulocytes, B- and T-lymphocytes, dendritic cells, mast cells, platelets, 
intestinal epithelial cells, astrocytes, neurons and tumor cells (63, 71, 78-85).  Once released 
from their cells of origin exosomes can travel locally and systemically to interact with local and 
distant cells.  
Exosomes can be characterized by the enrichment of certain proteins known as exosomal 
markers as compared to cell lysates.  These exosomal markers have a range of function and 
include: polypeptides associated with antigen presentation, adhesion molecules, membrane 
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transport and fusion, heat-shock proteins, cytoskeletal proteins, and raft-associated proteins and 
glycolipids (62, 63, 84, 86-89).  One of the first observations of these markers occurred when the 
protein composition of exosomes derived from murine DCs, human intestinal epithelial cell 
(IECs), and EBV-transformed human B lymphocytes all showed common proteins.  These 
included but were not limited to CD86, CD63, CD9, CD 37, CD53, CD81, CD82, HSC70, 
HSP84/90, Annexins, Rab 7, Rab 2, ALIX and TSG101 (62).  A vast majority of these are now 
known as exosomal makers and used to characterize exosomes.  While there is a significant 
amount of similarities between exosomes secreted from the various cell types there are also 
remarkable differences, which is seen when the protein composition of exosomes secreted from 
reticulocyte, lymphocytes and dendritic cells are compared.  Red cell exosomes contain the 
transferrin receptor, a major component of reticulocyte plasma membrane; however, lymphocyte 
and dendritic cell derived exosomes show little to no transferrin receptor.  In contrast these 
exosomes are rich in MHC Class I and II complexes, undoubtedly reflecting their cell of origin 
(64, 67, 75, 79).  With the protein composition of all exosomes being unique it is important to 
understand the fate of these extracellular vesicles once released. 
Typically, exosomes will travel systemically to a distant cell where they will partake in one of 
three forms of communication with the recipient cell.  The three mechanisms by which exosomes 
are believed to interact with recipient cells are shown in Figure 1.2.  The first two mechanisms, 
internalization and membrane fusion, result in the transfer of exosomal membrane and cytosolic 
material to the recipient cell; this could include oncogenic proteins, mRNAs and miRNAs (57, 
64, 75).  The third mechanism by which exosomes interact with distant cells is through 
ligand/receptor interactions.  Through this mechanism, exosomes are able to interact with the 
distant cell in a similar fashion to two cells communicating with one another; however, without 
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the need for direct cell-cell contact.  Upon binding of the receptor and ligand the exosome 
activates a signaling pathway in the recipient cell leading to changes in gene expression and 
phenotype (57, 64, 75).  Because of their content, ability to travel systemically, and different 
modes of communicating with distant cells exosomes can be seen as packaged delivery systems, 
capable of delivering material from the cell of origin; such as microRNA, nucleic acids, and 
proteins; to distant cells in the body. 
Due to their communication capabilities exosomes, specifically tumor-derived exosomes, have 
shown to play an important role in tumorigenicity.  Tumor-derived exosomes are capable of 
inducing phenotypic changes in non-neoplastic cells promoting an environment for further tumor 
development.  In particular tumor-derived exosomes have been shown to play roles in: enhancing 
metastasis by preparing new tumor niches, inducing neoplastic transformation, increasing 
angiogenesis, inducing anti-tumor immune evasion, educating and recruiting macrophages and 
fibroblast and lastly promoting drug resistance (57, 90, 91).  For these reasons tumor-derived 
exosomes are thought to have a vital role in the overall development and progress of cancer. 
In addition to the important roles exosomes play in cancer development, the biogenesis and 
output of exosomes has been shown to be elevated in cancer cells and often times correlates with 
the clinical status of the patient (92-94).  Coupled with the fact exosomes are extremely stable 
compared to circulating proteins and nucleic acids (95) and can be easily isolated from a variety 
of biological fluids such as blood, ascites, urine, saliva and malignant effusions exosomes are 
ideal targets for biomarker discovery (96-102).  For example, in one study exosomes derived 
from patients with melanoma were assessed as diagnostic and prognostic biomarkers.  Melanoma 
biomarkers, MIA and S100B, were detectable in the exosomes of patients and the exosomal 
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concentrations correlated with serum concentrations of the biomarkers.  Following analysis the 
exosomal associated MIA and S100B proved to have as much diagnostic and prognostic utility 
as the serum markers currently used (90).  In another study, conducted by Melo and colleagues, 
exosomes expressing Glypican-1 were able to detect early pancreatic cancer with 100% 
specificity and sensitivity (103, 104).  In both of these studies exosomes secreted as a byproduct 
of tumors were interrogated and utilized for novel diagnostic purposes. 
Of increased interest, exosomes have also been evaluated as potential biomarkers for ovarian 
cancer.  In one study exosomes were captured from plasma of ovarian cancer patients, patients 
with benign disease and healthy controls.  The total exosome number and protein content was 
significantly greater for exosomes captured from patients with disease as opposed to benign 
disease and healthy controls (105, 106).  Utilizing exosomes as biomarkers for ovarian cancer 
has also been performed through the examination of miRNA.  In one such study performed by 
Taylor and colleagues the levels of miRNAs in exosomes was examined for ovarian cancer 
patients, patients with benign disease and healthy controls.  The miRNA expression was 
significantly higher for patients with the disease as opposed to benign disease and undetectable 
in healthy controls.  Of the seven miRNAs examined the expression of two, miR-200c and miR-
214, showed correlation with staging of the tumor  (107).  Overall this data and others support 
the utility of exosomes as a source of biomarkers for a range of malignant conditions.  Because 
of the many unique advantages exosomes harbor, they could play a vital role in the advancement 
of blood based assays or liquid biopsies. 
According to Roche and the National Institute of Cancer at the National Institute of Health a 
liquid biopsy is a simple and non-invasive blood test to examine tumor-circulating byproducts, as 
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a means gaining molecular information regarding the tumor.  Most commonly liquid biopsies are 
used to analyze circulating tumor DNA (ctDNA), circulating tumor cells (CTC), tumor-relevant 
protein molecules and miRNAs (108-115).  Genotyping of a tumor is the best strategy in 
determining the most beneficial treatment option for a patient.  However, tissue samples 
collected during biopsies typically only provide a snapshot of the tumor environment and are not 
representative of the intratumor heterogeneity (116-118).  Noninvasive blood-based liquid 
biopsies can provide a means of monitoring therapy-related markers and molecular changes 
throughout tumor progression, providing crucial information for patient management (116).  
Novel research in the field of exosomes has been aimed at implementing exosomes as a 
surrogate for tumor liquid biopsies (105, 118-122).  This is largely a result of tumors continually 
secreting exosomes, as well as exosomes being strongly representing of their cell of origin (118).  
Changes in the tumor environment will more rapidly be reflected in exosomes than through 
biomarkers that are typically measured in circulation.  For this reason, liquid biopsies using 
exosomes is a novel method to provide accurate information regarding response to treatment and 
progression of the tumor environment over time. 
With this growing interest in utilizing exosomes for liquid biopsies microfluidic devices are 
being developed to automate and expedite the isolation of exosomes and ultimately analysis.  
One such device was developed in our lab integrating immunomagnetic isolation and 
enrichment, chemical lysis, and immune-sandwich chemifluorescence probing in one sequential 
process.  This microfluidic device or “lab-on-a-chip” was developed to capture non-small cell 
lung cancer (NSCLC) and ovarian cancer-associated exosomes and showed that exosomal 
protein markers could accurately distinguish cancer cases from healthy individuals (123).  Of 
most importance, the complete analysis was completed in ~2 hrs (0.5 hrs off-chip incubation and 
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~1.5 hrs on-chip assay) with as low as 30 µL of plasma samples, compared to up to ten hours 
required for traditional isolation and 1 mL of plasma required.  There are many other types of 
devices that exist which utilize different platforms and technology to capture exosomes including 
size-exclusion chromatography, surface plasmon resonance, membrane filters and magnetic 
sensing, as well as antibodies and affinity agents (123-127).  The future of early detection as well 
as disease monitoring is contingent on developing devices such as the one developed by He and 
colleagues which focus on isolating and analyzing tumor-derived exosomes as biomarkers.  Not 
only do these assays have the potential to offer high specificity and sensitivity they are non-




Figure 1.1 Biogenesis of exosomes.  The plasma membrane undergoes endocytosis to form the 
early endosome.  Inward budding and a series of maturing steps occur to form the late endosome 
from the early.  Reversed budding of the late endosome leads to the formation of the 
multivesicular body (MVB).  The MVB can be trafficked to the lysosome for degradation or to 
the plasma membrane where it can be fused and exosomes released into the extracellular milieu. 




Figure 1.2 Different methods for exosome communication with recipient cells.  1. Fusion of 
the exosome membrane to the plasma membrane of the recipient cell, exchanging membrane and 
cytosolic material.  2. Endocytosis of the exosome resulting in exchange of membrane and 
cytosolic material.  3. Ligand/Receptor interaction between the exosome and recipient cell 
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Depleting Plasma of microvesicles and exosomes. Prior to removal of extracellular vesicles 
(EVs), 50 µl of plasma was reserved for downstream proteomic studies.  Three 150 µL aliquots 
of plasma from 14 patients diagnosed with stage III/IV ovarian carcinoma were centrifuged at 
100,000 x g for one hour to pellet all EVs, including exosomes, using a Beckman Airfuge 
ultracentrifuge.  EVs and exosomes pelleted were pooled for each patient. 
Proteomic Studies. Milliplex® Human Circulating Cancer Biomarker Panel 1 Immunoassay 
(Millipore cat#HCCBP1MAG-58K) containing 23 cancer related biomarkers (Table 2) was used 
to measure the concentrations of analytes in: plasma of EOC patients, plasma of EOC patients 
depleted of EVs, cell cultured derived EVs, primarily exosomes, cell culture derived 
subpopulations of EVs, primarily exosomes (CA125+), as well as patient derived immune-
purified extracellular vesicles including exosomes (CA125+, EpCAM+, and FAPa+).  From the 
immunoassay, Median Fluorescent Intensity (MFI) data using a 5-parameter logistic or spline 
curve-fitting method was used to calculate analyte concentrations as per manufacturers’ 
guidelines. 
Immunomagnetic bead and antibody coupling. Streptavidin-coated magnetic microbeads 
(Dynabeads MyOne, 1 µm in diameter) were purchased from ThermoFisher Scientific. 
Antibodies against CA125, EpCAM, and FAP-α were coupled to the Dynabeads through biotin-
streptavidin linkage, per manufacturer’s instructions.  Linkage of CA125, EpCAM, and FAP-α to 
Dynabeads was performed utilizing a 30-minute incubation time at room temperature, with 20 µg 
of biotinylated antibody per 1 mg of beads.  20 µL of antibody-coated beads (1 mg/mL) was 
mixed with 150 µL human plasma or 150 µL of purified cell culture derived EVs, primarily 
exosomes.  Dynabeads coupled to antibodies against CA125, EpCAM, and FAP-α, were 
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incubated with the samples for 30 minutes at room temperature.  Captured EVs and exosomes 
were released from the Dynabeads through incubation at 65˚C for 5 minutes to break the biotin-
streptavidin bond.  EVs and exosomes were lysed by 5% Triton X-100 with agitation for 5 
minutes.    
Biotinylating Antibodies for Immunoprecipitation.   EpCAM and FAPa antibodies purchased 
from R&D Systems (Catalog Number: MAB960 and MAB3715-500) were biotinylated using 
Thermo Scientific EZ-Link Sulfo-NHS-Biotin following manufacturer’s protocol for 
biotinylating proteins in solution.  Following steps to label the antibodies Zeba Spin Desalting 
Columns 7KMWCO were used to remove excess biotin.  An aliquot of purified labeled antibody 
was taken for protein assay.  
Patient plasma samples.  Human blood samples were collected from healthy donors and 
ovarian cancer patients under protocol HSC #5929 (Biospecimen Repository Core Facility, 
Director, Andrew Godwin).  De-identified samples were obtained from the University of Kansas 
Cancer Center’s BRCF after approval from the internal Human Subjects Committee. 
Cell Culture. We utilized the human ovarian cancer cells A1847, and OVCAR3 as 
representative epithelial ovarian cancer cell lines (128).  Ovarian cancer cell lines have been 
authenticated by using multiplex short tandem repeat (STR) testing and compared to historical 
reference DNA preserved in the lab for these cell lines.  Testing was performed by the Clinical 
Molecular Oncology Lab at KUMC, a CLIA/CAP-accredited molecular diagnostics laboratory 
using the Promega PowerPlex 16 System used for human identity testing run on an Applied 
Biosystems instrument.   Both cell lines were cultured in RPMI-1640 (Gibco, Thermo Fisher) 
media supplemented with 10% (v/v) exosome-depleted FBS, 2 mm L-glutimine, 0.2 units/mL 
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human insulin, and 100 units per mL penicillin-streptomycin at 37°C with 5% CO2.  Exosome-
depleted FBS was obtained by centrifuging FBS for 18 hours at 100,000 x g followed by 
filtration through a 0.22 µm filter. 
Exosome Isolation. Cell lines were cultured to 70-80% confluency in complete media. 
Conditioned media was collected after 24-48 hours and pooled.  Exosomes were isolated by 
differential centrifugation as previously reported (64).  Briefly, media was spun for 10 minutes at 
2000 x g to isolate cell debris, 45 minutes at 10,000 x g to pellet large vesicles, and twice at 
100,000 x g to pellet and wash exosomes.  Exosome pellets were resuspended in 50-100 µL of 
cold PBS.  
CA125 Enzyme-Linked Immunosorbent Assay (ELISA).  RayBio® Human CA125 ELISA 
Kit (RayBiotech cat#ELH-CA125) was used to quantify circulating CA125 levels in plasma of 
EOC patients and controls, as well as plasma of EOC patients and controls depleted of EVs 
including exosomes, following manufacturer’s protocol. 
Nanoparticle Tracking Analysis. Purified exosomes from cell culture as well as exosomes and 
microvesicles isolated from plasma samples using immunoprecipitation were analyzed using a 
NanoSight LM10 instrument (NanoSight, Salisbury, United Kingdom).  Analysis was performed 
by applying a monochromatic 404 nm laser to diluted samples and measuring the Brownian 
movements of each particle.  The Nanoparticle Tracking Analysis software version 2.3 was used 
to analyze five 60 second videos from different fields of view were collected for each sample and 
averaged to give mean, mode, and median vesicle size as well as concentration of particles. 
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Statistical Analysis.  Statistical analysis was performed using a two tailed Student’s t-test on 
Graph Pad Prism Program.  To reduce the probability of making a Type I error Bonferroni 
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Cancer related biomarkers detected in plasma are in free circulation as well as associated 
with extracellular vesicles. 
Exosomes are known to carry a wide range of proteins representative of their cell of origin 
making them excellent biomarker candidates (64, 67, 75, 79, 118).  In one study, exosomes 
containing the biomarker Glypican-1 were capable of detecting pancreatic cancer from benign 
disease with absolute specificity and sensitivity (103, 104).  With tumors generating a significant 
amount of exosomes and extracellular vesicles as compared to normal cells is it possible that 
cancer biomarkers typically measured in plasma are actually associated with tumor derived 
extracellular vesicles in circulation as opposed to in free circulation?  To investigate this further 
a Luminex multiplex panel of 23 cancer related biomarkers, shown in Table 2, was utilized to 
analyze whole blood plasma as well as plasma depleted of all EVs, from patients diagnosed with 
advanced stage (III/IV), high grade serous ovarian cancer.  Through the comparison of the 
analyte concentrations in plasma to the plasma depleted of all extracellular vesicles (PDEV) we 
gain an understanding of where these cancer related biomarkers can be located, in free 
circulation or in direct association with EVs. 
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Table 2: List of analytes examined in the Milliplex® Human Circulating Cancer Biomarker 
Panel 1 Immunoassay 
Human Circulating Cancer 
Biomarker Panel 1 
AFP CA125 












Plasma samples were depleted of EVs including exosomes through ultracentrifugation using the 
Airfuge ultracentrifuge.  Both whole plasma and PDEV were analyzed with the Luminex 
multiplex panel using a 1:6 dilution.  The concentration of each analyte in the plasma as well as 
PDEV is shown in Figure 3.1.  It is important to note that while 23 analytes were investigated, 
signal was detectable for 20 markers.  For the other three analytes (SCF, CYFRA21-1, and b-
HCG), the concentration was outside of the lower detection limit (SCF: 2.0 pg/mL, CYFRA21-1: 
59.3 pg/mL, b-HCG: 0.029 mU/mL).  TRAIL, Leptin, and OPN show a small, but statistically 
significant decrease in the PDEV as opposed to the whole plasma based on a paired t-test 
(TRAIL and Leptin: P<0.05, OPN: P<0.001).  However, when the statistical analysis is corrected 
for using the Bonferroni correction, only OPN shows a statistical decrease in the PDEV, Figure 
3.2.  This decrease in biomarker concentration suggests that when the EVs including exosomes 
are removed from the plasma, a portion of the circulating analyte is depleted; representing a 
potential association between the analyte and the EVs.  In contrast, the concentration of the 
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remaining analytes does not show a statistically significant decrease following the removal of 
extracellular vesicles and exosomes. 
Current screening methods for ovarian cancer include monitoring CA125 levels.  The CA125 
used for diagnostic purposes showed to be mostly free circulated as opposed to microvesicle-
associated.  This is shown in Figure 3.1 and Figure 3.2 with data from the Luminex panel as 
well as with data from a CA125 specific ELISA (Figure 3.4.A).  There is not a statistically 
significant difference in the concentration of CA125 measured in the plasma as compared to the 
PDEV.  Taken together this data suggest that a majority of the cancer biomarkers studied in this 
panel are relatively low or potentially absent in extracellular vesicles and that the signal detected 
is attributed primarily to analytes in free circulation. 
Cell line derived exosomes contain subpopulations with varying levels of cancer related 
biomarkers, implying there is heterogeneity within the exosome populations. 
Exosomes were isolated from conditioned media of A1847 and OVCAR3 ovarian cancer cell 
lines through ultracentrifugation (64).  Immunoprecipitation was used to select for exosomes 
expressing CA125 on the surface.  Using MyOne streptavidin coated beads coupled with a 
biotinylated antibody against CA125, exosomes expressing CA125 were selected for from the 
whole exosome population isolated.  The CA125+ exosomes as well as the whole exosome 
population were lysed and analyzed using the same Luminex multiplex panel of 23 cancer 
related biomarkers.  The concentration of each analyte for the two populations is shown in 
Figure 3.3, for both cell lines.  In both A1847 and OVCAR3 derived extracellular vesicles, the 
analyte concentration for the CA125+ population does not match that of the whole exosome 
population, suggesting cargo of these subpopulations differ and there is heterogeneity among the 
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cell culture derived exosomes.  In exosomes from A1847 there are some analytes such as MIF, 
IL-8, HGF, sFas, CA 19-9, and b-HCG where the concentrations were lower in the CA125+ 
exosomes as compared to the whole exosome population.  This is attributed to the CA125+ 
population only contributing to a fraction of the observed signal detected in the whole exosome 
population.  In addition, there are other analytes such as prolactin, SCF, CYFRA 21-1, OPN, 
FGF-2, and HE4 in A1847 and MIF, Leptin, IL-6, sFasL, HGF, sFas, prolactin, SCF, CYFRA 
21-1, OPN, FGF-2, HE4, and VEGF in OVCAR3 where the concentration is higher in the 
subpopulation as compared to the entire population.  When this subpopulation is enriched for, the 
signal for these biomarkers is also enriched for, which can result in > 300-fold increase in the 
analyte concentration.   
While these exosomes were both derived from ovarian cancer cell lines there are striking 
differences between the protein levels of the exosomes.  This is likely a result of the 
heterogeneity of the disease itself.  For instance, when the CA125+ population is selected for in 
OVCAR3 exosomes the concentration of MIF, HGF, and CA 19-9 is enriched for, as depicted by 
an increase in concentration from the whole exosome population.  However, in the CA125+ 
population of the A1847 derived exosomes these signals are not enriched for.  In contrast there 
are some analytes that are enriched for in the CA125+ population of both cell line derived 
exosomes, such as Leptin, CYFRA 21-1, HE4 and OPN.   
At least three subtypes of extracellular vesicles can be isolated from patients with stage III 
and IV ovarian cancer, of which heterogeneity can be observed in the levels of 23 
biomarkers studied. 
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The subpopulations of extracellular vesicles observed in the A1847 and OVCAR3 cell lines are 
also observed in vesicles derived from clinical plasma samples of women with stage III/IV high 
grade serous ovarian cancer.  Using the same amount of whole plasma (150 μL), 
immunoprecipitation was used to select for exosomes and extracellular vesicles expressing 
CA125, EpCAM, or FAP-a on the surface.  Epithelial cell adhesion (EpCAM) is a 30- to 40-kDa 
membrane protein expressed by a variety of human epithelial cells, but is overexpressed and 
homogenously expressed on the surface of cancer cells(144).  EpCAM, while it is not specific 
for ovarian cancer, has been shown to be expressed on the surface of ovarian cancer derived 
exosomes (145).  While little research has been done with FAP-a  and extracellular vesicles, it is 
understood that expression is restricted to pathologic sites such as cancer (146).  For the cell 
culture related data, the starting material used was ovarian cell line derived exosomes isolated 
via the widely accepted method of differential centrifugation.  In contrast, these extracellular 
vesicles (CA-125+, EpCAM+, and FAP-a+) were isolated directly from plasma using immune-
capture,  which contains a diverse population of vesicles within the circulation as opposed to 
solely exosomes.  For this reason, they are representative of a wider population of extracellular 
vesicles.  When the Luminex multiplex panel of 23 cancer related biomarkers is used to compare 
the three subpopulations (CA-125+, EpCAM+, and FAP-a+) of extracellular vesicles there are 
differing concentrations for each analyte within the subtypes.  Some analytes such as AFP, MIF, 
Leptin, and HGF levels are relatively consistent between the three subtypes while other analytes 
such as CEA, sFas, prolactin, CYFRA 21-1, OPN, HE4, and CA125 vary between the three 
populations (Figure 3.4).  This observation is most likely attributed to the subtypes being 
secreted from different cell types resulting in differences in the cargo and the levels of protein in 
the immuno-captured vesicles.   
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Enrichment of CA125+ EVs results in increased limit of detection between EOC patients 
and healthy controls. 
When a woman presents with symptoms of ovarian cancer that persist for more than two weeks 
her physician would likely request a CA125 blood test and/or a TVUS.  As discussed in Chapter 
1, the problem with both of these screening methods is the lack of specificity and sensitivity, 
which was seen when we measured circulating CA125 in cases and controls (Figure 3.5.A).  
Any screening strategy for ovarian cancer must have an exceptionally low false positive rate in 
order to achieve a low and acceptable number of unnecessary operations per screen-detected 
case.  Given the relatively low prevalence in the general population (1 in 2,500), an effective 
screening strategy must not only have a high sensitivity for early-stage disease (>75%), but also 
a very high specificity (99.6%) to prompt less than ten operations for each ovarian cancer case 
diagnosed (a minimum positive predictive value of 10%), which represents a generally accepted 
limit for balancing risk with benefit among practitioners and advocates (37, 147-149).  
Therefore, we began to explore if EVs could serve as new biomarkers and/or complement 
existing screening approaches. 
EVs were immuno-captured with antibodies against CA125 and EpCAM from 150 µL of plasma 
of EOC cases and controls.  Following the immuno-capture the EVs were lysed and evaluated 
using the Luminex multiplex panel (Figure 3.6).  Importantly, even in this very limited samples 
set; we observe up to a 13-fold elevation in CA125 for patients with ovarian cancer compared to 
controls (Figures 3.5.B and 3.6).  Although it is not possible to establish sensitivity or specificity 
from this limited sample set, our results show a clear separation between cases and controls when 
we enrich for the CA125+ subpopulation of EVs and then measure the total CA125 
concentrations.  This is most likely a result of the concentration of CA125 within each 
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microvesicle being greater, as a similar amount of vesicles were isolated from both cases and 
controls (Figure 3.6).  This pilot study suggests that we are likely measuring a different form of 
CA125 than what is traditionally measured with an ELISA.  The typical ELISA for CA125 
measures a free circulating form of the protein while the immunoprecipitation is isolating 
vesicles with the membrane associated form of the protein, essentially acting as a different 
biomarker than the cleaved form (Figure 3.5.C).  While the CA125 ELISA is capable of 
detecting the membrane associated form, it is important to note that the concentration detected in 
plasma of the cleaved circulating form is significantly greater than that of the EV associated 
form, thereby masking the differences observed between cases and controls due to the membrane 
associated form.  Thus, selecting for only the membrane associated form of CA125, we might be 
eliminating any background associated the cleaved form, which can be elevated above the 
clinical level that elicits concern (≥35U/ml) in benign and non-gynecologic malignancies.  One 
caveat to our detection approach is that since CA125 is cleaved and secreted by ovarian tumor 
cells, it may result in decreased levels of CA125 available on the surface of the tumor cell, 
potentially impacting the amount of tumor associated vesicles immuno-captured.  However, as 
shown in Figures 3.4 and 3.5 we are still able to efficiently immuno-capture and interrogate 
CA125 levels in ovarian cancer patients. 
This pilot study also included examining EpCAM+ EVs and comparing the relative analyte 
concentrations in the same cases and controls (Figure 3.5).  Interestingly, we observe lower 
levels of a few analytes in cases versus controls in EpCAM+ EVs.  For instance HE4, the second 
most common circulating marker used in ovarian screening studies (150), was higher in 
EpCAM+ EVs from control samples versus cases.  This was also observed for a number of other 
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growth factors and cytokines, including β-HCG, CEA, CYFRA21-1, IL8, Leptin, SCF, sFasL, 
TNF-α, and TRAIL.   
In our experiments, both the CA125+ and EpCAM+ vesicles were selected directly from plasma, 
thus the cell of origin for these vesicles is unknown and potentially different for the two 
subtypes, attributing to the differences observed in the concentration of sFasL, as well as other 
analytes.  Interestingly, even though these two subtypes may be a result of differing cells of 
origin there are trends between cases and controls that can be observed in both the EpCAM+ and 
CA125+ vesicles.  This is seen with CYFRA21-1 which is elevated in controls compared to the 
cases for both of these subtypes, indicating the decreases in EV associated CYFRA21-1 is 
potentially associated with disease state (Figure 3.6).  Plasma levels of CYFRA21-1 are 
monitored in cases of non-small-cell lung cancer (151, 152), indicating in diseased states the 
protein in secreted.  Therefore, we can speculate that when the protein becomes secreted, the 
intracellular levels are decreased and thus fewer proteins are available to be packaged into EVs.  
Taken together our studies demonstrate that subpopulations of EVs can offer specificity for 







Figure 3.1  Analytes detected from the Milliplex® Human Circulating Cancer Biomarker 
Panel 1.  A majority of analytes detected appear to be attributed to a free circulating form as 
opposed to directly associated with extracellular vesicles including exosomes. The 
concentrations for each biomarker in plasma (red) as well as plasma depleted of EVs (blue) is 








Figure 3.2  Analytes detected from the Milliplex® Human Circulating Cancer Biomarker 
Panel 1.  A majority of analytes detected appear to be attributed to a free circulating form as 
opposed to directly associated with extracellular vesicles including exosomes. The 
concentrations for each biomarker in plasma (red) as well as plasma depleted of EVs (blue) is 






Figure 3.3 Subpopulations of exosomes exist in cell culture derived EVs for which analytes 
can be detected at varying concentrations.  A,B. Analyte concentrations for whole EV 
population (orange) and the CA125+ subpopulation of EVs (green).  These EVs, primarily 
exosomes, were derived from the (A) OVCAR3 cell line and (B) A1847 cell line.  
Concentrations for CA19-9, CA125, and b-HCG are shown in U/mL with the remaining 20 






Figure 3.4 EV cytokine, growth factor and cancer molecule concentrations vary for three 
subtypes of EVs derived from clinical plasma samples.  Immunoprecipitation was performed 
using antibodies against CA125, EpCAM, and FAP-a, to isolate EVs from plasma (150 µL) of 
three patients presenting with stage III and IV ovarian cancer.  Three subtypes of EVs were 
isolated CA125+ (orange), EpCAM+ (green), and FAP-a+ (purple).  Protein quantity for the three 
populations were analyzed using the Milliplex® Human Circulating Cancer Biomarker Panel 1.  
Concentrations from the three individual patients were averaged for each biomarker and the 
standard deviation is represented by the error bars .  Concentrations for CA 19-9, CA-125, and b-




Figure 3.5 CA125 measured in CA125+ exosomes offers greater distinction between cases 
and controls than CA125 measured in plasma.  A. CA125 levels measured through standard 
ELISA in plasma (red) and plasma depleted of microvesicles (blue) for healthy controls (n=5) 
and patients (n=14) presenting with stage III/IV ovarian cancer.  B. CA125 levels measured in 
CA125+ immuno-captured exosomes with from patients presenting with stage III/IV ovarian 







Figure 3.6  EpCAM+ and CA125+ subtypes of EVs and exosomes present with differing 
levels of various analytes in both clinical samples and healthy controls.  Concentrations for 
each biomarker from the Luminex Milliplex® panel is shown for both the EpCAM+ and CA125+ 




Figure 3.7 Size and concentration of immuno-captured vesicles is relatively consistent 
regardless of antibody used for capture.  A. Concentration and B. size of vesicles immuno-
captured with antibodies against CA125, EpCAM, and FAP-a for high grade serous cases (red) 
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The role TRAIL, leptin, and OPN play in cancer development can offer a potential explanation 
for the observed decrease in concentration upon the removal of extracellular vesicles.  TRAIL or 
TNF-related apoptosis-inducing ligand is part of the TNF superfamily, capable of inducing 
apoptosis.  TRAIL selectively induces apoptosis in cancer cells.  Induction of apoptosis is 
through the extrinsic pathway involving formation of the Death-inducing signaling complex 
(Disc), a pathway independent of p53 (129, 130).  For this reason TRAIL-receptor agonists 
(TRAs) have been developed and are showing robust anticancer activity in preclinical studies 
(130).  Once apoptosis has been initiated and the cell has undergone condensing and 
fragmentation, apoptotic bodies, vesicles ranging in size from 100-400 nm are formed.  These 
apoptotic bodies, because of their size, were removed during the depletion of the plasma.  As 
TRAIL is associated with the cell undergoing apoptosis it will become part of and removed with 
the apoptotic bodies, resulting in the observed decrease in concentration. 
Leptin, which also showed a decrease in concentration with the removal of extracellular vesicles 
including exosomes, has been shown to play a significant role in cancer progression.  Leptin is 
known to assist in cell differentiation, proliferation and survival, through endocrine, autocrine, 
and paracrine signaling (131).  Increased leptin signaling has been shown in various forms of 
cancer to activate a multitude oncogenic pathways enhancing proliferation and decreasing 
apoptosis (131-133).  In addition, leptin signaling has shown to assist in acquisition of the 
mesenchymal phenotype, important for enhanced invasion and angiogenic properties of tumor 
cells (131, 133).  For these reasons it is crucial to the progression of tumor development for 
leptin to be secreted by cancer cells and bind to receptors on neighboring cancer cells and cells 
of the tumor microenvironment.  To date there have been no studies which solely focus on the 
association between leptin and extracellular vesicles including exosomes.  However, the role 
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EVs play in cell to cell communication may assist in some of this essential leptin signaling, 
which is supported by data shown in Figure 3.1 and 3.2.  The slight decrease in Leptin in the 
PDEV is suggestive that a portion of the leptin signaling that occurs in cancer cells is a result of 
extracellular vesicle or exosomes associated signaling.  Similar to leptin, osteopontin (OPN) has 
been shown to promote tumorigenicity and metastasis so it is possible EVs including exosomes 
play a similar role with OPN as they do with leptin (134, 135).  In a study conducted by Monika 
and colleagues OPN was significantly elevated in peritoneal fluid of patients with ovarian cancer 
compared with patients with other gynecological conditions (135).  Interestingly, Atay and 
colleagues (unpublished data from the Godwin laboratory) have determined that the circulating 
exosome levels are increased by 12-fold in the plasma of EOC patients (0.711 x1011 ± 0.03 
particle/mL of initial plasma (n=17)) versus age-matched healthy donors (control) [0.06 x1011 ± 
0.01 particle/mL of initial plasma (n=11 samples)], and by 56-fold in ascites fluids of EOC 
patients [3.35 x1011 ± 12.7 particle/mL of initial plasma (n=14)] when compared to controls.  
This and other findings support the idea that increased levels of OPN measured in plasma from 
EOC patients may be in part associated with circulating EVs.  Overall, we found that when EVs 
were removed from plasma there was a decrease in TRAIL, leptin, and OPN concentrations 
suggesting an association between the analytes and vesicles.  Further, it may also suggest a role 
for these EVs and analytes in EOC development and progression. 
While the isolation of exosome subpopulations in cell culture derived exosomes was initially 
unexpected, others have reported on these subpopulations, and their ability to be distinguished 
and isolated from one another using a sucrose density gradient, as these subpopulations often 
have different densities.  Suggesting this heterogeneity observed in these exosome population is 
not unique to these two cell lines (136-139).  In one study conducted by Willms and colleagues it 
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was reported that cells release distinct exosome subpopulations, and that these subpopulations 
have unique composition.  In this study it was also reported that these subpopulations had the 
ability to elicit differential effects on recipient cells (136).  Furthermore, Bobrie et al. have 
suggested that common protocols for exosome isolation co-purifies vesicles from the endosomal 
origin as well as other origins.  As this protocol was used for our studies, it may be possible that 
the “exosomes” isolated from OVCAR3 and A1847 cells actually represent a diverse 
extracellular vesicle population.  The different extracellular vesicle populations observed in these 
studies, as well as our own, can be closely linked to the biogenesis of exosomes.  During 
biogenesis different MVBs are formed within the cell and the ILVs that form the MVBs are all 
different in morphology and composition, therefore variation in exosome populations can be 
expected (140-143). 
This heterogeneity observed in the cell culture derived exosomes is supports the idea of utilizing 
exosomes as biomarkers.  For example, selecting exosomes expressing CA125 on the surface 
and measuring another cancer related marker such as HE4, CYFRA21-1 or OPN, all markers 
where the signal is enhanced in this CA125+ subpopulation, may prove to be a better biomarker 
than simple analyzing a single analyte in circulation.  Previous studies attempting to use 
multimarker screening in ovarian cancer have coupled CA125, and HE4 which is supported by 
the HE4 signal being enriched for when vesicles expressing CA125 on the surface are selected 
for (36).  Based on this and previous studies, the combination of markers to select for a subtype 
of vesicles and evaluate specific proteins within this population may prove to be a valuable 
technique in discrimination between ovarian cancer and other benign gynecological conditions. 
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The particles that have been selected for from plasma using immunoprecipitation represent 
vesicles in circulation and can be derived from any given cell in the body, not just the cancer 
cells.  Because the cargo in exosomes and extracellular vesicles is highly representative of their 
cell of origin, if these vesicles are derived from different cell types it would explain the 
differences observed in the proteomic profile.  Regardless of their source these vesicles can be 
isolated using immunoprecipitation and interrogated for various cancer markers, expressed at 
varying levels for the three subpopulations studied.   
When these subpopulations of EVs were analyzed in clinical samples and controls, we noted an 
unexpected elevation in cancer related analytes for the controls compared to cases in EpCAM+ 
EVs. We hypothesize that this may be the result of the biogenesis of these immune-captured 
molecules.  Typically, growth factors are secreted and bind to cell surface receptors and trigger 
intracellular signaling cascades, resulting in cell proliferation and/or differentiation.  Cytokines 
are a subtype of growth factors that are produced by hematopoietic and immune cell types, and 
include interferons and interleukins.  They are able to inhibit, as well as stimulate, cell 
proliferation and differentiation.  Overproduction of growth factors and dysregulation of 
cytokine signaling are common features of malignancies.  Our results might suggest that in 
ovarian cancer and other malignancies, these factors are rapidly secreted from cells independent 
of EVs and are therefore at lower levels in the tumor cells and are not as efficiently shuttled 
to/captured in EVs.  
Finally, it is important to note that the level for some markers (i.e., b-HCG, CEA, CYFRA21-1, 
sFas, and sFasL) are increased in EVs immuno-captured with EpCAM as compared to CA125.  
This could potentially be associated with the expression level of CA125 and EpCAM within the 
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tumor cell.  In one study by Kloudová and colleagues the mRNA expression of 21 tumor 
associated antigens was examined in 41 patients with stage III/IV high grade serous epithelial 
ovarian cancer.  This study showed that the mRNA expression of EpCAM was elevated 
compared to CA125 in primary tumor cells.  Therefore, it is possible the vesicles isolated using 
EpCAM contain more tumor associated EVs which is reflected by elevated levels of multiple 
cancer biomarkers compared to the CA125 population.  This is also seen when the levels of 
sFasL are compared for CA125+ and EpCAM+ EVs.  sFasL levels are elevated in EpCAM+ EVs 
compared to CA125+ EVs, for both cases and controls.  Based on this observation it appears that 
sFasL is more strongly associated with vesicles that express EpCAM on the surface, which could 
be a result of the origin, i.e., primarily EpCAM+ tumor cells, of these EVs.  Although the number 
of vesicles isolated with EpCAM is similar to that of CA125 (Figure 3.6), it is possible that the 
vesicles isolated using EpCAM are more heterogeneous in their origin than CA125+ EVs. 
Overall, while the concentration of vesicles isolated based on their surface phenotype does not 
differ widely, the content within these vesicles is immensely different between EOC cases and 
healthy controls.  These differences observed in the subpopulations is likely a result of the 
diseased state as well as the origin of the vesicles.  For these reasons, we believe that examining 
subpopulations of EVs offers a unique strategy for evaluating novel and existing biomarker, with 














Chapter 5. Conclusion  
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The lack of precise early warning signs is one of the factors that contribute to the high mortality 
rate of ovarian cancer, with only 15% of ovarian tumors identified at stage I, when the disease 
can be cured in up to 90% of cases (1-3).  Current screening methods include serum cancer 
antigen 125 (CA125), which has proven to be inadequate for early detection due to its low 
sensitivity and specificity (153-155).  The focus of this study was to evaluate and examine 
extracellular vesicles, primarily exosomes, as potential sources of new biomarkers for early 
detection of ovarian cancer. 
This is the first study of our knowledge to measure and compare growth factors and cytokines in 
total plasma and plasma-depleted of extracellular vesicles.  An association was shown between 
three cancer related markers (TRAIL, Leptin, and OPN) EVs, as upon the removal of EVs the 
concentrations of these three markers decreased.  Each of these markers is shown to play an 
important role in the development of cancer; therefore it would be of interest to investigate to 
what extant EV associated communication plays a role in their tumorigenic signaling.  In 
addition, based on our study it appears that the form of CA125 measured clinically with a blood 
test is distinct from the protein measured in and on EVs from circulation.  It would be of interest 
to investigate further the similarities and differences between the two forms of CA125 in an 
effort to gain a better understanding of the roles played in ovarian cancer.   
The presence of subtypes of EVs was shown in vesicles isolated from conditioned media of 
ovarian cancer cell lines.  These subtypes were also observed in plasma samples of patients with 
stage III/IV ovarian cancer as well as healthy controls.  The three subtypes detected in clinical 
samples (EpCAM+, CA125+, and FAP-α+) all presented with varying levels of the 23 cancer 
related markers studied.  This is a proof-of-principle study to begin to better understand the 
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content of EOC-derived EVs and their utility as biomarkers that can be evaluated using a 
microfluidic device, similar to the one developed by He and colleagues (123).  Based on the 
cytokines, growth factors, and cancer molecules studied; measuring CA125 in the CA125+ 
subpopulation of EVs offers potential in distinguishing cases from controls.  Considering these 
findings were in a pilot study of only three cases and three controls it will be essential in future 
studies to expand to larger sample sets.  If these findings are consistent they could fairly easily be 
translated over for use with the microfluidic device, using CA125 as the capture agent to 
enumerate particle numbers and in turn measure CA125 in the captured and lysed vesicles. 
It is important to note that this study was limited to three subpopulations of EVs and the potential 
number of subpopulations is endless.  Studies are proposed in the Godwin laboratory to use these 
three subpopulations for deep global mass spectrometric (MS) analysis of the exosome preps 
using a novel Simple Nano-Proteomic Platform (SNaPP) specifically tailored for improving 
proteomic coverage and quantitative reproducibility in characterization of small-sized biological 
samples in order to define the proteome of ovarian cancer-associated exosomes.  These studies 
have developed the necessary techniques to allow for Phase I protein discovery experiments.  
Although, there may be a better and more specific capture agent for ovarian cancer-derived EVs, 
based on this limited pilot case/control study we found that using CA125 or EpCAM as the 
capture agents, and subsequently measuring CA125 and CYFRA21-1, respectively, may offer 
improved specificity and sensitivity for ovarian cancer.  Time will tell once expanded sample 
sets become available and are evaluated. 
Overall, these and other studies provide the framework for the initial characterization of 
circulating ovarian cancer-derived EVs and exosomal protein discovery for future development 
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of microfluidic-based devices utilized for screening purposes.  This study shows that there are 
subpopulations of EVs in plasma samples of women with ovarian cancer as well as healthy 
individuals.  Each of these subpopulations has a unique protein content which can be measured 
and used for analysis as biomarkers.    
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